XXXX . A risk factor for @entity6677 ?

@entity1 @entity3610 @entity6677 @entity28 @entity2690 @entity413
We investigated the impact of pregestationally elevated @entity2690 plasma levels on glycemic control in pregnant @entity1 with @entity3610 ( @entity3610 ). Twelve @entity1 with @entity3610 who became pregnant within six months following evaluation of their metabolic status were the study subjects. Four were @entity28 and six (two @entity28 ) had a hyperinsulinemic response to the oral @entity413 tolerance test (OGTT). They were tested with the OGTT at 28-30 weeks of gestation. We also tested 12 normal @entity1 and 10 consecutive @entity1 with @entity6677 ; all were at the same gestational age. Plasma levels of @entity2690 and @entity413 were determined in the samples collected for a period of four hours after @entity413 load (100 g). All @entity3610 @entity1 significantly increased their @entity2690 secretion in pregnancy. The hyperinsulinemic @entity3610 @entity1 developed @entity6677 (two @entity1 ) and impaired gestational @entity413 tolerance (three @entity1 ). The area under the @entity2690 curve was greater in @entity3610 @entity1 than in control and @entity6677 @entity1 (P < .01). In spite of their large increase in @entity2690 secretion observed during pregnancy, @entity1 with @entity3610 may develop a derangement of glycemic control, probably related to their pregestational insulinemic status.
